EA202190888A1 - Пептид для применения в косметике - Google Patents

Пептид для применения в косметике

Info

Publication number
EA202190888A1
EA202190888A1 EA202190888A EA202190888A EA202190888A1 EA 202190888 A1 EA202190888 A1 EA 202190888A1 EA 202190888 A EA202190888 A EA 202190888A EA 202190888 A EA202190888 A EA 202190888A EA 202190888 A1 EA202190888 A1 EA 202190888A1
Authority
EA
Eurasian Patent Office
Prior art keywords
peptide
cosmetic applications
photoaging
prevention
sequence
Prior art date
Application number
EA202190888A
Other languages
English (en)
Russian (ru)
Inventor
Пабло Пеллегрини
Original Assignee
Колоссиум Комбинаториал Кемистри Сентр Фо Текнолоджи Сосьета А Респонсабилита' Лимитата Ин Форма Аббревиата К4Т С.Р.Л.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Колоссиум Комбинаториал Кемистри Сентр Фо Текнолоджи Сосьета А Респонсабилита' Лимитата Ин Форма Аббревиата К4Т С.Р.Л. filed Critical Колоссиум Комбинаториал Кемистри Сентр Фо Текнолоджи Сосьета А Респонсабилита' Лимитата Ин Форма Аббревиата К4Т С.Р.Л.
Publication of EA202190888A1 publication Critical patent/EA202190888A1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/81Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • A61K8/8129Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an alcohol, ether, aldehydo, ketonic, acetal or ketal radical; Compositions of hydrolysed polymers or esters of unsaturated alcohols with saturated carboxylic acids; Compositions of derivatives of such polymers, e.g. polyvinylmethylether
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/185Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04Dispersions; Emulsions
    • A61K8/042Gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37Esters of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64Proteins; Peptides; Derivatives or degradation products thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73Polysaccharides
    • A61K8/735Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA202190888A 2018-10-11 2019-10-10 Пептид для применения в косметике EA202190888A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102018000009384A IT201800009384A1 (it) 2018-10-11 2018-10-11 Peptide for cosmetic application
PCT/IB2019/058641 WO2020075108A1 (en) 2018-10-11 2019-10-10 Peptides for use in treating and preventing skin aging and photo-aging

Publications (1)

Publication Number Publication Date
EA202190888A1 true EA202190888A1 (ru) 2021-07-07

Family

ID=65010824

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190888A EA202190888A1 (ru) 2018-10-11 2019-10-10 Пептид для применения в косметике

Country Status (13)

Country Link
US (1) US20210395305A1 (enExample)
EP (1) EP3863728A1 (enExample)
JP (1) JP2022508676A (enExample)
KR (1) KR20210075098A (enExample)
CN (1) CN112823039A (enExample)
AU (1) AU2019357261A1 (enExample)
BR (1) BR112021006742A2 (enExample)
CA (1) CA3115025A1 (enExample)
EA (1) EA202190888A1 (enExample)
IL (1) IL282064B (enExample)
IT (1) IT201800009384A1 (enExample)
SG (1) SG11202103026YA (enExample)
WO (1) WO2020075108A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202000020287A1 (it) * 2020-08-20 2022-02-20 Colosseum Combinatorial Chemistry Centre For Tech Societa A Responsabilita Limitata In Forma Abbrevi Peptide per applicazioni terapeutiche in campo dermatologico
KR102774179B1 (ko) * 2021-09-29 2025-03-04 (주)케어젠 항노화 활성을 갖는 펩타이드 및 이의 용도
KR102726837B1 (ko) * 2021-09-29 2024-11-07 (주)케어젠 항노화 활성을 갖는 펩타이드 및 이의 용도
KR102736940B1 (ko) * 2021-09-30 2024-12-03 (주)케어젠 항노화 활성을 갖는 펩타이드 및 이의 용도
KR102877905B1 (ko) * 2021-09-30 2025-10-30 (주)케어젠 항노화 활성을 갖는 펩타이드 및 이의 용도

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196055B2 (en) 1994-08-31 2007-03-27 Trustees Of Boston University Inhibition of apoptosis in keratinocytes by a ligand of p75 nerve growth factor receptor
GB9616105D0 (en) * 1996-07-31 1996-09-11 Univ Kingston TrkA binding site of NGF
AU7154698A (en) * 1997-04-25 1998-11-24 Genentech Inc. Ngf variants
US6664230B1 (en) * 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
MEP31508A (hr) 2003-07-15 2010-10-10 Amgen Inc Humana anti-ngf neutrališuća antitijela kao selektivni ihibitori ngf signalne kaskade
ME00226B (me) 2004-07-15 2011-02-10 Medarex Llc Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
EP2144615A4 (en) * 2007-04-06 2011-02-16 Kai Pharmaceuticals Inc METHOD OF USE OF GAMMA INHIBITOR COMPOUNDS FOR PAIN LIFTING
IT1394690B1 (it) * 2008-10-23 2012-07-13 Carli De Metodo di trattamento dermocosmetico della cute mediante applicazione di composizioni contenenti ngf.
KR101520333B1 (ko) * 2008-11-25 2015-05-14 (주)아모레퍼시픽 글루타밀아미도에틸 인돌을 함유하는 항노화용 화장료 조성물
EP2547365A1 (en) 2010-03-17 2013-01-23 Abbott Research B.V. Anti-nerve growth factor (ngf) antibody compositions
IE20100174A1 (en) * 2010-03-25 2012-02-29 Trinity College Dublin Transdermal administration of peptides
FR2961814B1 (fr) * 2010-06-29 2014-09-26 Isp Investments Inc Nouveaux peptides activateurs de la sirtuine 6 et composition cosmetique ou pharmaceutiques les comprenant.
JP6042343B2 (ja) * 2010-11-18 2016-12-14 スティーヴン ヨーリン 毛髪成長のための組成物及び方法
ITRM20110574A1 (it) * 2011-11-02 2013-05-03 Sampo S R L Preparato topico per indurre la pigmentazione cutanea e per il trattamento di discromie cutanee e vitiligine.
EP3352853B1 (en) * 2015-09-22 2022-09-21 Johnson & Johnson Consumer Inc. Methods for enhancing topical application of a benefit agent
KR20170049299A (ko) * 2015-10-28 2017-05-10 경상대학교산학협력단 성장인자와 사이토카인을 포함하는 조성물
CN107286233B (zh) * 2016-04-13 2020-11-06 舒泰神(北京)生物制药股份有限公司 低痛神经生长因子突变体
CN107973848B (zh) * 2017-12-28 2020-10-16 未名生物医药有限公司 一种从混合物中分离天然序列神经生长因子的方法

Also Published As

Publication number Publication date
JP2022508676A (ja) 2022-01-19
KR20210075098A (ko) 2021-06-22
EP3863728A1 (en) 2021-08-18
AU2019357261A1 (en) 2021-05-13
BR112021006742A2 (pt) 2021-09-21
IL282064A (en) 2021-05-31
SG11202103026YA (en) 2021-04-29
WO2020075108A1 (en) 2020-04-16
US20210395305A1 (en) 2021-12-23
IL282064B (en) 2022-09-01
IT201800009384A1 (it) 2020-04-11
CA3115025A1 (en) 2020-04-16
CN112823039A (zh) 2021-05-18

Similar Documents

Publication Publication Date Title
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
MX388822B (es) Composiciones que comprenden peptido wkdeagkplvk.
EA202190960A1 (ru) Конденсированные пирролины, которые действуют как ингибиторы убиквитин-специфической протеазы 30 (usp30)
WO2019045248A3 (ko) 주름 개선 활성을 나타내는 펩타이드 및 이의 용도
EA201990298A1 (ru) Способы и композиции для лечения рака
EA201891183A1 (ru) Композиции, содержащие натуральные экстракты, и их применение для кожи и волос
MX2022015725A (es) Inhibidores peptidicos ciclicos de la proteina 95 de la densidad post-sinaptica (psd-95) y usos de los mismos.
EA202192288A1 (ru) Соединения на основе нейрегулина-4 и способы их применения
EP3441082A4 (en) PEPTIDE WITH EFFECT TO INCREASE TELOMERASE ACTIVITY AND TELOMER EXTENSION AND COMPOSITION THEREFOR
EP3719032A4 (en) COMPOSITION FOR THE PREVENTION OR TREATMENT OF HAIR LOSS
ECSP20083339A (es) Proteínas inmunodominantes y fragmentos en esclerosis múltiple
EA202190057A1 (ru) Солюбилизированные апиразы, способы и применение
EA202092820A1 (ru) Композиция для расслабления мышц
EA202190310A1 (ru) Белок для лечения воспалительных заболеваний
MX390418B (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso.
PH12020500029A1 (en) Cosmetic compositions and methods of use
EA201590601A1 (ru) Применение pedf-производных полипептидов для лечения остеоартрита
EP3804728C0 (en) COMPOSITION COMPRISING AS ACTIVE INGREDIENT AN INOTODIOL COMPOUND INTENDED FOR THE PREVENTION OR TREATMENT OF ALLERGIC DISEASES
BR112016026637A2 (pt) associação de um tetrapeptídeo e um gliceril éster para tratamento de alopecia androgênica
EA202090470A1 (ru) Композиция для личного ухода
EA202090971A1 (ru) Способы применения и композиции, содержащие дулаглутид
EA202191446A1 (ru) Композиции для улучшения сексуальной функции
EA202092691A1 (ru) Соединения для устранения боли, композиции, содержащие их, и способы их применения
SA521422315B1 (ar) ببتيدات لعلاج مرض السكرى والاضطربات ذات الصلة والوقاية منها
EA201690966A1 (ru) Новое соединение для лечения тяжелой гипогликемии